Tier 3 — preclinical

Pharmacokinetics and bioequivalence of acetylcysteine granules among Chinese healthy volunteers under fasting and postprandial conditions

Jingjing Wang, Wanggang Zhang
Clin Pharmacol Drug Dev 2026 15(2):e1605

Bibliography

PubMed
PMID 40939146
DOI
10.1002/cpdd.1605
Funding
Funding disclosure was not located in the indexed record reviewed; consult the source publication for the full funding statement.
Competing interests
Competing-interest disclosure was not located in the indexed record reviewed; consult the source publication for the full declaration.

Study snapshot

DesignRandomized bioequivalence pharmacokinetic studies
ModelHuman
Sample34 fasting and 38 postprandial participants
InterventionAcetylcysteine granules under fasting and fed conditions
DurationSingle-dose pharmacokinetic studies
EndpointsAUC; Cmax; Bioequivalence; Food effect; Safety

What the study showed, in plain terms

2026 human pharmacokinetic work examining acetylcysteine granules under fasting and postprandial conditions.

Key findings

Provides contemporary formulation-specific exposure and food-effect data for oral acetylcysteine.

What this study can and cannot tell us

Healthy-volunteer bioequivalence research; not an efficacy study and not directly transferable to all supplement formulations.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology